



(51) International Patent Classification:

C07D 475/00 (2006.01) C07D 487/04 (2006.01)
C07D 475/10 (2006.01)

(21) International Application Number:

PCT/IB2010/002655

(22) International Filing Date:

24 September 2010 (24.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/245,773 25 September 2009 (25.09.2009) US

(71) Applicant (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHARRIER, Jean-damien** [FR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DURRANT, Steven** [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **O'DONNELL, Michael** [IR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).





(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS



(57) Abstract: A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the steps of: a) reacting a compound represented by Structural Formula (A) with FTNR^1R^7 under suitable conditions to form a compound represented by Structural Formula (B); and b) i) when R^{12} is $-\text{NO}_2$, and R^{11} is $-\text{OR}^{14}$: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form a compound represented by Structural Formula (II); and 2) optionally reacting the compound represented by Structural Formula (II) with $\text{R}^9\text{-LG}_2$, wherein LG_2 is a suitable leaving group, to form the compound represented by Structural Formula (I), wherein R^8 is R^9 ; or ii) when R^{12} is halogen, and R^{11} is $-\text{NHR}^{13}$: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form the compound represented by Structural Formula (I); and 2) optionally, when R^{13} is $-\text{H}$, reacting the compound produced from step b), ii), 1) with $\text{R}^9\text{-LG}_2$, wherein LG_2 is a suitable leaving group, to form the compound represented by Structural Formula (I) wherein R^8 is R^9 .